𩺠å
§ç§å°ç§èåç
1ïžâ£ MAC Pulmonary Treatment Decisions
- Treat all immunocompromise + symptomatic + radiographic progression
- Asymptomatic with stable imaging: surveillance OK
- Pretreatment AST (especially macrolide)
- Consider toxicity vs benefit (long course)
- Lady Windermere: 2-3Ã/wk dosing acceptable (less GI toxicity)
2ïžâ£ Inhaled Amikacin Liposomal (Arikayce)
- FDA 2018 for refractory MAC lung
- Direct delivery to lung
- Hopes for better pulmonary penetration with less systemic toxicity
- Caveat: ototoxicity, persistent culture, bronchospasm
- ID consult
3ïžâ£ Hot Tub Lung
- HP-like (hypersensitivity pneumonitis from M. avium inhalation)
- CT: ground-glass + small nodules
- BAL: lymphocytic
- Avoidance of hot tub usually resolves
- Steroid for severe
- Not antibiotic primarily
4ïžâ£ M. abscessus + CF
- Increasing recognition
- Lung transplant evaluation: M. abscessus complex â relative contraindication (varies by center)
- Aggressive treatment pre-transplant
- Genome sequencing for cluster identification
- Strict cohort segregation in CF clinics
5ïžâ£ Cardiac Surgery + M. chimaera
- 2014-2017 global outbreak (LivaNova heater-cooler units)
- 50,000+ patients exposed
- Late presentation (median 17 months post-op)
- Symptoms: fever, fatigue, sweat, hepatitis, prosthetic valve endocarditis, cytopenia, vision loss
- æ²»ç: rifabutin + clarithromycin + ethambutol + amikacin 6-12+ mo; sometimes prosthetic explant
- Hospital surveillance + manufacturer device alerts
6ïžâ£ Cosmetic Procedure Outbreaks
- M. fortuitum, M. chelonae, M. abscessus
- Inadequately sterilized equipment, contaminated solutions
- 2024: ongoing global awareness
- Reporting + investigation
- Surgical clinic infection control
7ïžâ£ NTM Lymphadenitis in Children
- Surgical excision = preferred (cure with single procedure)
- Antibiotic alone slower + variable outcome
- å€§å€ painless cervical mass < 5 yr
- Histology + culture
- Confirm species (M. avium most, also M. scrofulaceum, M. haemophilum)
- Postoperative course: monitor for sinus tract / recurrence
8ïžâ£ NTM AST
- Specialty labs (CDC, university)
- Broth microdilution standard
- MAC: clarithromycin most important
- M. abscessus: macrolide (erm gene check), amikacin, cefoxitin, imipenem
- M. kansasii: rifampin
- Resistance patterns species-specific
9ïžâ£ å¥ä¿ / Taiwan
- å¥ä¿ covers TB drugs (rifampin, INH, EMB, PZA, clarithromycin, etc.)
- NTM-specific: amikacin, clofazimine, imipenem etc. typically restricted indication
- éå ±: pulmonary NTM not éå ± like TB but case-by-case
- ç§é«åž« hint: è幎 + bronchiectasis + chronic cough + CXR ç°åžž + ç° AFB+ â ç¢ºèª species (TB vs NTM); æ²»ç plan differs
10. Future + Vaccines
- No NTM vaccine
- Surveillance + early treatment
- Improved diagnostics (PCR, MALDI-TOF)
- New drugs in development (bedaquiline activity vs MAC under study)
- Combination + duration optimization ongoing